Mustapha Hajjou

Mustapha Hajjou

Auto-generated profile, based on publicly available information

Mustapha Hajjou

Global Health Impact Programs, United States Pharmacopeial Convention, Rockville, Maryland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
GNGaurvika M. L. Nayyar
Gaurvika M. L. Nayyar
JBJoel G. Breman
Joel G. Breman
TMTimothy Ken Mackey
Timothy Ken Mackey
JCJohn P. Clark
John P. Clark
MHMustapha Hajjou
Mustapha Hajjou
JHJames E. Herrington
James E. Herrington
Falsified and substandard medicines are associated with tens of thousands of deaths, mainly in young children in poor countries. Poor-quality drugs exact an annual economic toll of up to US$200 billion and contribute to the increasing peril of antimicrobial resistance. The WHO has emerged recently as the global leader in the battle against poor-quality drugs, and pharmaceutical companies have increased their roles in assuring the integrity of drug supply chains. Despite advances in drug quality surveillance and detection technology, more efforts are urgently required in research, policy, and field monitoring to halt the pandemic of bad drugs. In addition to strengthening international and national pharmaceutical governance, in part by national implementation of the Model Law on Medicines and Crime, a quantifiable Sustainable Development Goal target and an international convention to insure drug quality and safety are urgent priorities.

3 June 2015 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
MHMustapha Hajjou
Mustapha Hajjou
LKLaura Krech
Laura Krech
CLChristi Lane-Barlow
Christi Lane-Barlow
LRLukas Roth
Lukas Roth
VPVictor S. Pribluda
Victor S. Pribluda
PLPatrick H. Lukulay
Patrick H. Lukulay
Monitoring the quality of medicines plays a crucial role in an integrated medicines quality assurance system. In a publicly available medicines quality database (MQDB), the U.S. Pharmacopeial Convention (USP) reports results of data collected from medicines quality monitoring (MQM) activities spanning the period of 2003–2013 in 17 countries of Africa, Asia, and South America. The MQDB contains information on 15,063 samples collected and tested using Minilab® screening methods and/or pharmacopeial methods. Approximately 71% of the samples reported came from Asia, 23% from Africa, and 6% from South America. The samples collected and tested include mainly antibiotic, antimalarial, and antituberculosis medicines. A total of 848 samples, representing 5.6% of total samples, failed the quality test. The failure proportion per region was 11.5%, 10.4%, and 2.9% for South America, Africa, and Asia, respectively. Eighty-one counterfeit medicines were reported, 86.4% of which were found in Asia and 13.6% in Africa. Additional analysis of the data shows the distribution of poor-quality medicines per region and by therapeutic indication as well as possible trends of counterfeit medicines.

1 February 2013 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MHMustapha Hajjou
Mustapha Hajjou
YQYanyan Qin
Yanyan Qin
SBSanford Bradby
Sanford Bradby
DBDaniel Bempong
Daniel Bempong
PLPatrick Lukulay
Patrick Lukulay